Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORAKLE: Lorlatinib in ALK+ NSCLC After 2nd-Gen TKI Failure
NCT04111705Phase 2Completed
- Sponsor
- IFCT
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by IFCT. Primary endpoint: Objective Response Rate at 6 weeks. Started Aug 2020; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04111705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111705.